[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peptic-ulcer-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peptic-ulcer-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637972","phase-4-vonoprazan-high-dose-dual-vs-levofloxacin-concomitant-100637972",false,"NCT07624422","Vonoprazan High-Dose Dual VS Levofloxacin Concomitant","Efficacy and Safety of Vonoprazan High-Dose Dual Therapy Compared to Levofloxacin Concomitant Therapy for H. Pylori Eradication: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years (adjust upper limit as needed)\n* Confirmed Helicobacter pylori infection by at least one of the following: positive urea breath test, rapid urease test, histopathology, or stool antigen test\n* Treatment-naïve for H. pylori (no prior eradication therapy) - OR - prior treatment failure (specify if rescue therapy)\n* Willing and able to provide written informed consent\n* Willing to adhere to the 14-day treatment regimen and follow-up visits\n* For women of childbearing potential: negative pregnancy test and agreement to use effective contraception during the treatment period\n\nExclusion Criteria:\n\n* History of allergy or hypersensitivity to vonoprazan, amoxicillin, clarithromycin, metronidazole, or any other penicillin\u002Fcephalosporin\n* Previous H. pylori eradication therapy (if study is for first-line treatment)\n* Active gastrointestinal bleeding or perforation\n* Severe liver disease (Child-Pugh class B or C) or severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnancy or breastfeeding\n* Concurrent use of medications with significant drug-drug interactions (e.g., warfarin, phenytoin, digoxin, atazanavir, rilpivirine)\n* Malignancy or any life-threatening condition with life expectancy \\\u003C 6 months\n* Participation in another interventional trial within 30 days prior to enrollment\n* Any condition that, in the investigator's opinion, precludes safe participation or adherence to the protocol","ALL","18 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a randomized controlled trial comparing the efficacy and safety of two vonoprazan-based regimens: high-dose dual therapy (vonoprazan plus a single antibiotic) versus triple therapy (vonoprazan plus two antibiotics) for the treatment of H. pylori infection).\n\nParticipants will be randomly assigned to receive either regimen for 14 days. The primary outcome is eradication rate , and secondary outcomes include adverse events and treatment adherence.",[27,28,29],"Helicobacter Pylori Infection","Peptic Ulcer Disease","Gastritis",[27,31],"Vonoprazan","NOT_YET_RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":21},"2026-11-01",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Damascus Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100634280","phase-4-vonoprazan-based-versus-esomeprazole-based-triple-therapy-for-helicobacter-pylori-eradication-100634280","NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal",{"count":53,"type":21},80,[24],"The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[27,57,28,58,59],"Dyspepsia","Helicobacter Pylori","H Pylori",[61,62,31,63,64,65,57],"Helicobacter pylori","Helicobacter pylori eradication","Esomeprazole","Levofloxacin","Triple therapy","RECRUITING","2026-04-18",{"date":69,"type":36},"2026-04-22",{"date":71,"type":21},"2026-04-15",{"date":73,"type":21},"2026-08-14",{"name":75,"class":43},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100628196","predicting-peptic-complications-using-h-pylori-serology-and-gastric-ultrasound-100628196","NCT07458490","Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound","H. Pylori Serology and Gastric Ultrasound Findings in Predicting Peptic Complications","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) presenting with dyspeptic symptoms (epigastric pain, nausea, vomiting, heartburn).\n* Patients with suspected or confirmed peptic ulcer disease.\n* Patients presenting with acute complications (hematemesis, melena, acute - abdominal pain suggestive of perforation).\n* Patients with history of peptic ulcer disease requiring surveillance.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Previous gastric surgery (gastrectomy, vagotomy).\n* Active malignancy (gastric cancer, lymphoma).\n* Previous H. pylori eradication therapy within 4 weeks.\n* Current use of proton pump inhibitors (PPIs) within 2 weeks (may affect antibody levels and ultrasound findings).\n* Severe coagulopathy or bleeding disorders (INR \\>2.0).\n* Pregnancy.\n* Poor quality ultrasound images due to excessive bowel gas or obesity.\n* Hemodynamically unstable patients requiring immediate intervention.\n* Refusal to participate in the study.",{"count":85,"type":21},230,"OBSERVATIONAL","This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease (PUD). Peptic ulcer complications, such as stomach bleeding or perforation, are serious and typically require an invasive procedure called an upper endoscopy for diagnosis and treatment.\n\nResearchers want to find out if these two non-invasive tests can be used together to create a reliable risk-scoring system. This system would help doctors quickly identify which patients are at a high risk for complications and need an urgent endoscopy, compared to those who are at a lower risk and can be safely monitored without the invasive procedure.\n\nThe study will include adult patients presenting with stomach symptoms (like pain, nausea, or heartburn), as well as those with suspected or confirmed peptic ulcer disease. Participants will provide a blood sample to check for H. pylori antibodies and undergo a standard, painless abdominal ultrasound to examine the thickness of their stomach wall. An upper gastrointestinal endoscopy will be performed if it is clinically necessary as part of the patient's standard medical care.",[28,89,27,90,57],"HELICOBACTER PYLORI INFECTIONS","Peptic Ulcer",[92,93,94,28,27,95,57],"H. pylori serology","gastric ultrasound","peptic complications","Peptic Ulcer Complications","2026-03-04",{"date":98,"type":36},"2026-03-09",{"date":100,"type":21},"2026-04",{"date":102,"type":21},"2027-05",{"name":104,"class":43},"Assiut University"]